Observational studyRheumatology (Oxford, England)2026
Malignancy rates in children, young people and adults with JIA: an observational study using CPRD Aurum.
Observational study in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesJIA affects ∼1-2/2000 children in the UK. Adults with inflammatory arthritis have ∼10% increased malignancy risk. JIA malignancy rates in Nordic data are 3-5/10 000 person years, with conflicting evidence on comparative risk. This study calculated malignancy rates in England of patients with JIA, vs matched controls and general population estimates.
methodsUsing UK Primary Care data (CPRD) Aurum, this retrospective cohort study matched patients with JIA (diagnosed <16 years) 4-to-1 with non-JIA controls in England by birth year, gender and practice. Malignancies were identified from (i) NHS-linked hospitalization data and (ii) CPRD read codes. Exposure started at first JIA code date (or matched date for controls), 1 January 2000, or CPRD entry date, whichever was latest. Follow-up continued until end of follow-up of JIA-matched patient (for controls), end of CPRD follow-up, 31 December 2018, first malignancy or death, whichever was first. Cox-proportional hazards models compared malignancy rates. Standardized incidence ratios (SIRs) were calculated against ONS general population estimates by calendar year, age and gender.
resultsA total of 3714 patients with JIA and 10 858 matched controls were identified; demographics were similar. Malignancy rates were 6.8 per 10 000 (95% CI: 4.4-10.7) in JIA and 3.1 per 10 000 person years (95% CI: 2.0-4.6) in controls; HR 2.2 (95% CI: 1.2-4.1). Both cohorts had raised SIRs compared with ONS general population estimates.
conclusionsThis study found that those with JIA had a doubling risk for malignancies compared with the matched control population. However, it is important to note that malignancy in this JIA patient population is extremely rare with the absolute risk remaining very low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.